Scribe Therapeutics Inc.
NASDAQ:SCTXBiotechnology
-$0.91 today
- Market cap
- $255.19M
- Beta
- 0.00
Volume 0.27M
Average 0.98M
Returns on capital
Scribe Therapeutics Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
No return metrics data available.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Benjamin L. Oakes | Co-Founder, President, CEO & Chairman | USD 574.98K | 37 | 264.78K | 1.64% |
David L. Parrot | CFO & Treasurer | USD 475.83K | 57 | — | — |
Svetlana Lucas | Chief Operating Officer | USD 466.98K | 54 | 3.00K | 0.02% |
Jennifer A. Doudna | Co-Founder & Scientific Advisor | — | 62 | 0 | <0.01% |
David F. Savage | Co-Founder & Scientific Advisor | — | — | — | — |
Brett T. Staahl | Co-Founder & VP of External Innovation | — | — | — | — |
George Manning | VP & Controller | — | — | — | — |
Richard Hector | Head of Intellectual Property | — | — | — | — |
Sunny Mok | Senior Vice President of Operations | — | — | — | — |
Chitra Sharma | Senior Vice President of Development | — | — | — | — |
Stephen V. Thau | Secretary | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 27, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
8
$71.32M
Sells
0
$0.00
Net Transaction Value
+$71.32M
Net buying
Most Active
Aghazadeh Behzad
3 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Jul 28, 26Jul 28, 2026 | Aghazadeh Behzad Indirect | Buy | $144.3K$144,266.25 |
| Jul 27, 26Jul 27, 2026 | AH Bio Fund II, L.P. Indirect | Buy | $5M$4,999,995.00 |
| Jul 27, 26Jul 27, 2026 | GORDON CARL L Indirect | Buy | $15M$15,000,000.00 |
| Jul 27, 26Jul 27, 2026 | ORBIMED ADVISORS LLC Indirect | Buy | $15M$15,000,000.00 |
| Jul 24, 26Jul 24, 2026 | Aghazadeh Behzad Indirect | Buy | $1.1M$1,115,500.00 |
| Jul 24, 26Jul 24, 2026 | Aghazadeh Behzad Indirect | Buy | $35M$34,999,995.00 |
| Jul 23, 26Jul 23, 2026 | Lucas Svetlana Indirect | Buy | $45K$45,000.00 |
| Jul 23, 26Jul 23, 2026 | Parrot David Indirect | Buy | $20K$19,995.00 |
Summary
Insiders reported 8 buys worth $71.32M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $71.32M. Aghazadeh Behzad was the most active insider with 3 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
Competitors
Who does Scribe Therapeutics Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
No competitor data available.
Questions
Management questions
Common questions about SCTX's management, answered from reported figures.
Who manages SCTX?
Scribe Therapeutics Inc. (SCTX) lists 11 active executives. The top listed executive is Benjamin L. Oakes, Co-Founder, President, CEO & Chairman.
Are SCTX insiders buying or selling?
Recent insider activity shows net buying of $90.46M.
Continue the stock analysis
Jump to another research area for this company.